GlobeNewswire·Nov 9, 2026, 7:30 AM ET

Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

CYTK

Cytokinetics presented new aficamten data at the 2026 Hypertrophic Cardiomyopathy Medical Society & American Heart Association Scientific Sessions in Chicago.
ACACIA-HCM imaging sub-study results showed 36 weeks of aficamten treatment led to statistically significant reductions in left ventricular mass index & wall thickness in non-obstructive HCM patients.
Structural improvements in non-obstructive HCM correlated with decreased NT-proBNP & high-sensitivity troponin I, indicating reduced cardiac wall stress & myocardial injury independent of obstruction relief.
ACACIA-HCM patient-reported data revealed aficamten improved Kansas City Cardiomyopathy Questionnaire Overall Summary Scores by 4.0 points vs placebo at Week 36, with benefits increasing through Week 72.
Effects on patient-reported health status declined within four weeks of treatment withdrawal, with no differences remaining at study end.
FOREST-HCM long-term data from 410 obstructive HCM patients showed only 2.9% developed left ventricular ejection fraction <50%, with episodes being transient, asymptomatic, & rapidly reversible.
Borderline left ventricular ejection fraction (≥50% to <55%) was deemed clinically benign without requiring dose adjustment or intervention.
Cytokinetics plans to submit a Supplemental New Drug Application in Q4 2026 for aficamten in non-obstructive hypertrophic cardiomyopathy following positive ACACIA-HCM results.
MYQORZO remains approved for symptomatic obstructive HCM in the U.S., China, EU, UK, & Canada, with safety warnings regarding heart failure risk due to systolic dysfunction.
MYQORZO is available only through a restricted REMS program requiring certification for prescribers, patients, pharmacies, & distributors.
Contraindications include concomitant use of rifampin, & dosing requires monitoring for interactions with CYP450 inhibitors or inducers that alter aficamten blood concentrations.
Hypertension was the only adverse reaction occurring in >5% of patients more commonly than placebo in pivotal trials.

Company: Cytokinetics, Incorporated
Keywords: Nasdaq:CYTK, Cytokinetics, Incorporated, AHA, HCM, cardiology